

Special Issue

New Trends in SARS-CoV-2 Variants and Vaccines

Message from the Guest Editor

COVID-19 vaccines have been proven to be a game-changing tool in preventing severe cases of COVID-19. To date, four major vaccines have received approval from several countries. These vaccines are mainly based on two different forms of technology: (1) messenger ribonucleic acid (mRNA) vaccines produced by Pfizer-BioNT162b2 (BNT162b2) and Moderna (mRNA-1273), and (2) vector-based replication-deficient vaccines based on chimpanzee adenoviruses (ChAdOx1 nCoV-19, AZD1222 by AstraZeneca) and human cells (Ad26.COV2 by Janssen). Interpersonal differences in terms of the short- and long-term immune responses against SARS-CoV-2 infection after vaccination have been reported. The host genetics of the vaccine recipient and COVID-19 strains are central to the evaluation of the long-term sustainability of COVID-19 vaccines. Original research articles and reviews are invited for submission. The research areas of interest include (but are not limited to) host genetic markers, immune response markers, vaccine efficacies and COVID-19 strains, population-based COVID-19 vaccine efficacy studies, and the side-effects of COVID-19 vaccines. I look forward to receiving your contributions.

Guest Editor

Dr. Seik-Soon Khor

Singapore Centre for Environmental Life Sciences Engineering,
Nanyang Technological University, Singapore, Singapore

Deadline for manuscript submissions

closed (20 March 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/122254

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).